Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety

Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studi...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-06, Vol.10 (7), p.605-616
Main Authors: Creticos, Peter Socrates, Pfaar, Oliver
Format: Article
Language:English
Subjects:
Age
allergen immunotherapy
Allergens
Allergic rhinitis
allergic rhinitis/conjunctivitis
Allergies
Asthma
Clinical trials
Conjunctivitis
FDA approval
Immunotherapy
Oral administration
ragweed
ragweed pollen
ragweed subcutaneous immunotherapy
ragweed sublingual immunotherapy
ragweed sublingual tablet
Safety
Seasons
Statistical analysis
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0186